Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

IDT Biologika

- PMLiVE

Novavax’s BA.1 COVID-19 booster shows strong immune response in phase 3 trial

The trial included the company's bivalent vaccine, the BA.1-adapted vaccine and its prototype

- PMLiVE

AstraZeneca’s Farxiga shows benefits for heart failure patients in phase 3 trial

The SGLT2 inhibitor improved symptom burden, physical limitations and quality of life

- PMLiVE

Pfizer and BioNTech dose first patient in COVID-19/flu combination vaccine study

The vaccine aims to protect individuals against two severe respiratory viral diseases

- PMLiVE

AstraZeneca/Sanofi’s Beyfortus receives EC approval for prevention of RSV in infants

The decision makes the antibody the first broadly protective option for this age population

- PMLiVE

AstraZeneca and Medera’s Novoheart develop first human models of heart failure

The ‘heart-in-a-jar’ model will be used to effectively test drug candidates for HFpEF patient

- PMLiVE

EMA grants AZ’s Vaxzevria COVID-19 vaccine full marketing authorisation

Vaxzevria has been shown to be effective against all forms of COVID-19

- PMLiVE

Act-Accelerator outlines plans for longterm COVID-19 control

Its plan highlights key priorities as countries transition to manage the public health issue

- PMLiVE

NHS England hits ten million in autumn COVID-19 booster campaign

Health leaders have warned of a COVID-19 and flu ‘twindemic’ this winter

- PMLiVE

WHO reveals tuberculosis deaths rose due to COVID-19 disruption

An estimated 10.6 million were infected with TB in 2021, an increase of 4.5% from 2020

- PMLiVE

Alexion’s Ultomiris shows promise in neuromyelitis optica spectrum disorder phase 3 trial

Ultomiris-treated patients showed zero relapses with a median treatment duration of 73 weeks

- PMLiVE

AstraZeneca’s two advanced breast cancer trials meet primary endpoints

Both trials showed significant improvement in progression-free survival

- PMLiVE

BMS confirms COVID-19 vaccine immune response in Zeposia-treated MS patients

Over 92% of patients in the analyses mounted a serological response following vaccination

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links